Your session is about to expire
← Back to Search
Pharmacist care in conjunction with home blood pressure monitoring for High Blood Pressure
N/A
Recruiting
Led By Ross Tsuyuki, PharmD
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Established diagnosis or currently on treatment for hypertension.
No established diagnosis and/or treatment for hypertension.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24-weeks
Awards & highlights
Study Summary
This trial aims to investigate the effects of using home blood pressure monitoring in addition to pharmacist care compared to usual care in women with high blood pressure. The study will randomly assign participants to either receive the intervention
Who is the study for?
This trial is for women with high blood pressure who haven't been diagnosed or treated for hypertension, except those with diabetes where a lower BP threshold applies. Participants should have a systolic BP of at least 140 mmHg or diastolic BP of at least 90 mmHg, or at least 130/80 mmHg if diabetic.Check my eligibility
What is being tested?
The study tests whether home blood pressure monitoring plus pharmacist care improves blood pressure control compared to usual pharmacist care alone in women. It's a randomized controlled trial where half the participants will use home monitors and get enhanced pharmacy services, while the other half receives standard care.See study design
What are the potential side effects?
There are no direct side effects from participating in this trial as it involves non-invasive blood pressure monitoring and counseling by pharmacists rather than medication. However, there may be indirect effects such as anxiety from self-monitoring.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with or am being treated for high blood pressure.
Select...
I have never been diagnosed or treated for high blood pressure.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24-weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24-weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Difference in change in Systolic Blood Pressure
Secondary outcome measures
Adherence to Medications
Changes to antihypertensive medication regimen
Consultant Satisfaction
+3 moreTrial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Pharmacist care in conjunction with home blood pressure monitoringExperimental Treatment2 Interventions
Patients will have BP assessed at baseline in the pharmacy by the pharmacist, and they will receive a home blood pressure monitor in addition to education and counselling provided by the pharmacist. Patients will measure their BP at home for seven days every four weeks and input their results into a data management system called REDCap that is accessible by the pharmacist. The pharmacist will follow up with the patient every 4 weeks to review their readings and at 24-weeks the patient will come into the pharmacy for a final follow-up and BP readings. The pharmacist will fax BP readings as well as suggestions for therapy modification to the patient's prescribing clinician. Patients will then have their care returned to their prescribing clinician with no pharmacist specific interventions outside of usual pharmacy care activities and have a single follow-up at month-12 with the pharmacist reviewing home BP monitor use and reporting of data to prescribing clinician.
Group II: Usual pharmacist careActive Control1 Intervention
Patients will have BP assessed at baseline, 12-, and 24-weeks in the pharmacy by the pharmacist. Patients will not receive a home blood pressure monitor. Pharmacist will provide them usual care, education and counselling on BP management. Pharmacists will fax BP readings to the patient's prescribing clinician but will not provide any suggestions for therapy modification. After 24-weeks patients will be offered a home blood pressure monitor with education on its use. They will then be offered to crossover to the intervention group for the next 6-months or have their care returned to their prescribing clinician with no pharmacist specific interventions outside of usual pharmacy care activities and have a single follow-up at month-12 with the pharmacist reviewing home BP monitor use and reporting of data to prescribing clinician.
Find a Location
Who is running the clinical trial?
University of AlbertaLead Sponsor
889 Previous Clinical Trials
384,809 Total Patients Enrolled
Ross Tsuyuki, PharmDPrincipal InvestigatorUniversity of Alberta
1 Previous Clinical Trials
890 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any available vacancies for potential participants in this research study?
"Indeed, as stated on clinicaltrials.gov, this trial is currently actively seeking participants. The study was originally posted on January 9th, 2024 and has been recently updated on January 23rd, 2024."
Answered by AI
How many patients are currently undergoing treatment in this clinical trial?
"Indeed, the details on clinicaltrials.gov indicate that this research trial is actively seeking individuals to participate. The study was initially posted on January 9th, 2024 and last updated on January 23rd, 2024. A total of 368 participants are being recruited across 21 different locations."
Answered by AI
In how many different geographical areas can patients access this clinical trial?
"At present, the trial is accepting patients at 21 different sites. These locations are spread across various cities, including Omemee, Milton, and Etobicoke as well as several other locations. To minimize travel demands for participants, it is advisable to choose a site that is closest to your location."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger